Genzyme's CSR Dilemma: How to Play its HAND

Christopher A. Bartlett; Tarun   Khanna; Prithwiraj  Choudhury

Case | HBS Case Collection | August 2009 (Revised April 2012)

Genzyme's CSR Dilemma: How to Play its HAND

by Christopher A. Bartlett, Tarun Khanna and Prithwiraj Choudhury

Abstract

Genzyme, a global biotechnology company, launches a program to develop therapies for neglected diseases (e.g., malaria, TB), giving away the intellectual property. This case focuses on the decision of which diseases, which partnerships, and which markets should management decide to fund. But the bigger issue is how this program, developed under the umbrella role Genzyme's corporate social responsibility, fits into its global competitive strategy.

Keywords: Global Strategy; Health Care and Treatment; Intellectual Property; Corporate Social Responsibility and Impact; Partners and Partnerships; Research and Development; Biotechnology Industry;

Format: Print

23 pages

Educators Purchase

Citation:

Bartlett, Christopher A., Tarun Khanna, and Prithwiraj Choudhury. "Genzyme's CSR Dilemma: How to Play its HAND." Harvard Business School Case 910-407, August 2009. (Revised April 2012.)

In 2020, the largest non-governmental organization in the world, BRAC, headquartered in Dhaka, Bangladesh, has some big problems to tackle. Its founder, Sir Fazle Hasan Abed, has left behind a challenge: take the 1981-founded organization from Bangladesh to every single part of the world and create a global set of programs and program heads. Active in education, health, microfinance and poverty alleviation, BRAC is also entering the humanitarian and relief world through its work with Rohingya refugee camps in Bangladesh. What will be the way forward for this global NGO based in the South?

Pallak Seth, Group CEO of PDS Multinational Fashions, is contemplating options to bring better collaboration across his global apparel supply chain platform. PDS, a group of 50-plus subsidiary companies, each led by its own CEO and with different apparel industry specialties, has grown rapidly over the past decade, yet the industry is increasingly competitive and challenges remain constant. Looking for ways to reach the Group’s 2023 goals of $2 billion in revenue, Seth and his executive board are considering two ways to increase collaboration and reward performance: a joint P&L approach, to drive partnerships across the subsidiaries, and an employee stock option plan, to unlock value across the Group.

Faculty & Research

Genzyme's CSR Dilemma: How to Play its HAND

Abstract

Citation:

About the Authors

More from these Authors

Faculty & Research

Genzyme's CSR Dilemma: How to Play its HAND

Abstract

Citation:

Related Work

About the Authors

More from these Authors